All Stories

  1. Corrigendum to “Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma” [Modern Pathology. 2022;35(9):1181-1192]

    Article • Modern Pathology, February 2024, Elsevier

    Analyn Lizaso

  2. Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer

    Article • BMC Medicine, July 2023, Springer Science + Business Media

    Analyn Lizaso

  3. Blood-based DNA methylation profiling for the detection of ovarian cancer

    Article • Gynecologic Oncology, November 2022, Elsevier

    Analyn Lizaso

  4. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma

    Article • Modern Pathology, September 2022, Elsevier

    Analyn Lizaso

  5. The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling

    Article • Annals of Translational Medicine, April 2022, AME Publishing Company

    Analyn Lizaso

  6. Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements

    Article • npj Precision Oncology, March 2022, Springer Science + Business Media

    Analyn Lizaso

  7. Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

    Article • World Journal of Clinical Cases, March 2022, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Analyn Lizaso

  8. Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer

    Article • ESMO Open, February 2022, Elsevier

    Analyn Lizaso

  9. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

    Article • BMC Medicine, October 2021, Springer Science + Business Media

    Analyn Lizaso

  10. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients

    Article • Cancer Medicine, October 2021, Wiley

    Analyn Lizaso

  11. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

    Article • BMC Medicine, September 2021, Springer Science + Business Media

    Analyn Lizaso

  12. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance

    Article • Clinical Lung Cancer, May 2021, Elsevier

    Analyn Lizaso

  13. Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer

    Article • Frontiers in Oncology, April 2021, Frontiers

    Analyn Lizaso

  14. Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC

    Article • Journal of Thoracic Oncology, March 2021, Elsevier

    Analyn Lizaso

  15. Differences in the clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas from eastern China

    Article • Annals of Translational Medicine, March 2021, AME Publishing Company

    Analyn Lizaso

  16. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China

    Article • Medical Oncology, February 2021, Springer Science + Business Media

    Analyn Lizaso

  17. Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review

    Article • Hereditary Cancer in Clinical Practice, January 2021, Springer Science + Business Media

    Analyn Lizaso

  18. Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics

    Article • Journal of Cancer, January 2021, Ivyspring International Publisher

    Analyn Lizaso

  19. The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report

    Article • Annals of Translational Medicine, January 2021, AME Publishing Company

    Analyn Lizaso

  20. The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment

    Article • Translational Lung Cancer Research, January 2021, AME Publishing Company

    Analyn Lizaso

  21. The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report

    Article • Cancer Biology & Therapy, December 2020, Taylor & Francis

    Analyn Lizaso

  22. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer

    Article • European Journal of Cancer, December 2020, Elsevier

    Analyn Lizaso

  23. A reply to “MET-mutant cancer and immune checkpoint inhibitors: A large database analysis”

    Article • Lung Cancer, December 2020, Elsevier

    Analyn Lizaso

  24. A reply to “ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis”

    Article • Lung Cancer, December 2020, Elsevier

    Analyn Lizaso

  25. Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study

    Article • Lung Cancer, December 2020, Elsevier

    Analyn Lizaso

  26. Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma

    Article • Translational Lung Cancer Research, December 2020, AME Publishing Company

    Analyn Lizaso

  27. Third left pulmonary lobe

    Article • Thorax, November 2020, BMJ

    Analyn Lizaso

  28. The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based genomic profiling

    Article • November 2020, Springer Science + Business Media

    Analyn Lizaso

  29. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers

    Article • Lung Cancer, October 2020, Elsevier

    Analyn Lizaso

  30. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy

    Article • Journal of Thoracic Oncology, August 2020, Elsevier

    Analyn Lizaso

  31. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients

    Article • Lung Cancer, August 2020, Elsevier

    Analyn Lizaso

  32. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

    Article • Lung Cancer, August 2020, Elsevier

    Analyn Lizaso

  33. A Burning External Colon Cancer Patient With Diffuse Miliary Peritoneal Metastases

    Article • The American Journal of Gastroenterology, July 2020, Wolters Kluwer Health

    Analyn Lizaso

  34. <p>Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer</p>

    Article • OncoTargets and Therapy, July 2020, Taylor & Francis

    Analyn Lizaso

  35. Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing

    Article • Journal of Molecular Diagnostics, July 2020, Elsevier

    Analyn Lizaso

  36. Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer

    Article • Annals of Palliative Medicine, July 2020, AME Publishing Company

    Analyn Lizaso

  37. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients

    Article • Frontiers in Oncology, June 2020, Frontiers

    Analyn Lizaso

  38. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab

    Article • Lung Cancer, May 2020, Elsevier

    Analyn Lizaso

  39. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer

    Article • Aging, February 2020, Impact Journals, LLC

    Analyn Lizaso

  40. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC

    Article • Journal of Thoracic Oncology, February 2020, Elsevier

    Analyn Lizaso

  41. Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report

    Article • Translational Lung Cancer Research, February 2020, AME Publishing Company

    Analyn Lizaso

  42. Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method

    Article • Translational Lung Cancer Research, February 2020, AME Publishing Company

    Analyn Lizaso

  43. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes

    Article • Journal of Cancer Research and Clinical Oncology, January 2020, Springer Science + Business Media

    Analyn Lizaso

  44. Erratum to Prevalence and clinical significance of pathogenic germline <i>BRCA1/2</i> mutations in Chinese non-small cell lung cancer patients

    Article • Cancer Biology and Medicine, January 2020, Tsinghua University Press

    Analyn Lizaso

  45. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report

    Article • Therapeutic Advances in Respiratory Disease, January 2020, SAGE Publications

    Analyn Lizaso

  46. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

    Article • Journal of International Medical Research, December 2019, SAGE Publications

    Analyn Lizaso

  47. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients

    Article • Translational Lung Cancer Research, December 2019, AME Publishing Company

    Analyn Lizaso

  48. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report

    Article • Thoracic Cancer, November 2019, Wiley

    Analyn Lizaso

  49. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non‐small cell lung cancer patients

    Article • Thoracic Cancer, November 2019, Wiley

    Analyn Lizaso

  50. A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung

    Article • Modern Pathology, October 2019, Springer Science + Business Media

    Analyn Lizaso

  51. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next‐generation sequencing

    Article • Histopathology, October 2019, Wiley

    Analyn Lizaso

  52. Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report

    Article • Diagnostic Pathology, September 2019, Springer Science + Business Media

    Analyn Lizaso

  53. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients

    Article • Journal of Translational Medicine, August 2019, Springer Science + Business Media

    Analyn Lizaso

  54. Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients

    Article • Cancer Biology and Medicine, August 2019, Tsinghua University Press

    Analyn Lizaso

  55. Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders

    Article • Cancer Biology & Therapy, July 2019, Taylor & Francis

    Analyn Lizaso

  56. Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report

    Article • OncoTargets and Therapy, July 2019, Dove Medical Press

    Analyn Lizaso

  57. Detecting Ultralow Frequency Mutation in Circulating Cell‐Free DNA of Early‐Stage Nonsmall Cell Lung Cancer Patients with Unique Molecular Identifiers

    Article • Small Methods, April 2019, Wiley

    Analyn Lizaso

  58. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

    Article • Cancer Biology & Therapy, April 2019, Taylor & Francis

    Analyn Lizaso

  59. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling

    Article • Thoracic Cancer, February 2019, Wiley

    Analyn Lizaso

  60. SIM2 maintains innate host defense of the small intestine

    Article • AJP Gastrointestinal and Liver Physiology, December 2014, American Physiological Society

    Analyn Lizaso

  61. β-adrenergic receptor-stimulated lipolysis requires the RAB7-mediated autolysosomal lipid degradation

    Article • Autophagy, August 2013, Taylor & Francis

    Analyn Lizaso